Improved survival using multi-modality therapy in patients with lung metastases from colorectal cancer: A preliminary study

Inoue, Yasuhiro; Miki, Chikao; Hiro, Junichiro; Ojima, Eiki; Yamakado, Koichiro; Takeda, Kan; Kusunoki, Masato

doi:10.3892/or.14.6.1571

Cited by 23 publications

(22 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This finding suggests that the combination of lung RF ablation with systemic chemotherapy improves prognosis because most patients received systemic chemotherapy before and after lung RF ablation. Inoue et al reported a significant superiority in combination therapy to achieve a 3-year survival rate that is better than that obtained using systemic chemotherapy alone (87.5 vs. 33.3%) (20).…”

Section: Discussionmentioning

confidence: 98%

Long-term results of radiofrequency ablation in colorectal lung metastases: Single center experience

Yamakado

Inoue²,

Takao³

et al. 2009

Oncol Rep

View full text Add to dashboard Cite

Abstract. This study was undertaken to evaluate long-term results of radiofrequency (RF) ablation in patients with colorectal lung metastases and to stratify patients benefitting from lung RF ablation. Lung RF ablation was performed in 78 patients with 198 colorectal lung metastases. Safety, local tumor progression, and survival were evaluated retrospectively. The mean follow-up period after the 140 lung RF ablation sessions was 24.6±7.6 months. Pneumothorax and pleural effusion requiring chest tube placement occurred respectively in 18 (12.9%, 18/140) and 2 (1.4%, 2/140) sessions. The respective 1-, 3-and 5-year local tumor progression rates were 10.1% (95% CI, 2.9-17.3%), 20.6% (95% CI, 8.9-22.2%) and 20.6% (95% CI, 8.9-22.2%). The 1-, 3-and 5-year survival rates were 83.9% (95% CI, 75.2-92.7%), 56.1% (95% CI, 41.7-70.5%) and 34.9% (95% CI, 18.0-51.9%), with median survival time of 38.0 months. Univariate analysis revealed maximum tumor diameter of 3 cm or less, single-lung metastasis, lack of extrapulmonary metastasis and normal carcinoembryonic antigen (CEA) level as better prognostic factors. The latter two were significant independent prognostic factors. The 1-, 3-and 5-year survival rates were 97.7% (95% CI, 93.3-100%), 82.5% (95% CI, 68.2-96.8%) and 57.0% (95% CI, 34.7-79.2%) in 54 patients with no extrapulmonary metastases and 96.9% (95% CI, 90.8-100%), 86.1% (95% CI, 71.1-100%) and 62.5% (95% CI, 36.3-88.6%) in 33 patients with negative CEA levels. Lung RF ablation is a safe and useful therapeutic option. These identified prognostic factors will help to stratify patients who benefit from lung RF ablation.

show abstract

Section: Discussionmentioning

confidence: 98%

Long-term results of radiofrequency ablation in colorectal lung metastases: Single center experience

Yamakado

Inoue²,

Takao³

et al. 2009

Oncol Rep

View full text Add to dashboard Cite

show abstract

“…After percutaneous ablation of pulmonary metastatic lesions, the survival is 64 to 78% at 2 years and 27 to 57% at 5 years (26,29,30,41,44) (Table II). Results are significantly higher in case of combined ablation / chemotherapy than chemotherapy alone (87 versus 33%) (45).…”

Section: Pulmonary Metastasesmentioning

confidence: 93%

Percutaneous ablation of malignant thoracic tumors

Ghaye

2013

Journal of the Belgian Society of Radiology

View full text Add to dashboard Cite

Lung cancer is the leading cause of death related to cancer. Fifteen to thirty percent of patients with a localized lung cancer are actually inoperable as they present with poor general condition, limited cardiopulmonary function, or a too high surgical risk. Therefore, minimally invasive treatments are needed and percutaneous ablation seems an attractive option. Thermal ablation can be performed by delivering heat (radiofrequency, microwave, laser) or cold (cryotherapy) through a needle inserted into the tumor under CT guidance. The ideal lesion is less than 2 or 3 cm in diameter. Success of percutaneous thermal ablation appears to be close to those of surgery for localized lung cancer. Nevertheless studies are still needed to definitely assess the role of ablation compared to other emerging techniques, as stereo tactic radiotherapy as well as potential synergy with other treatments.

show abstract

“…Uracil inhibits hepatic dihydropyrimidine dehydrogenase, and thus enhances the plasma 5-FU level and antitumour activity of 5-FU (23). Our PMC regimen has improved the prognosis of patients with CRC over the past 10 years (12)(13)(14)(15)24). PMC showed an improved prognosis of irradiated rectal cancer with p53 overexpression (12).…”

Section: Discussionmentioning

confidence: 99%

Multicentre phase II study of leucovorin plus pharmacokinetic modulating chemotherapy for metastatic colorectal cancer

Inoue

Hiro²,

Toiyama³

et al. 2010

Oncology Letters

Self Cite

View full text Add to dashboard Cite

Abstract. The optimal administration of 5-fluorouracil (5-FU)/leucovorin (LV) for colorectal cancer (CRC) has yet to be fully defined although evidence of the combination has already been established. In a multicentre phase II study, pharmacokinetic modulating chemotherapy (PMC), which is based on the concept that continuous intravenous 5-FU infusion can be enhanced by low-dose oral uracil/tegafur, was combined with LV and administered. Thirty-seven patients were enrolled. The objective response rate was 31.4% and the tumour stabilization rate was 85.7%. The most common toxic effects were neutropenia and hand-foot skin reactions although no life-threatening grade 3-4 toxicities were noted. Grade 3 toxicities such as neutropenia, nausea, diarrhoea and oesophagitis occurred in one patient each. We identified the usefulness of a new type of infusional 5-FU combined with LV for the treatment of CRC. The combination of PMC and LV is active with an acceptable rate of toxicity as a first-line treatment of advanced CRC.

show abstract

Improved survival using multi-modality therapy in patients with lung metastases from colorectal cancer: A preliminary study

Cited by 23 publications

References 0 publications

Long-term results of radiofrequency ablation in colorectal lung metastases: Single center experience

Long-term results of radiofrequency ablation in colorectal lung metastases: Single center experience

Percutaneous ablation of malignant thoracic tumors

Multicentre phase II study of leucovorin plus pharmacokinetic modulating chemotherapy for metastatic colorectal cancer

Contact Info

Product

Resources

About